000 01357 a2200349 4500
005 20250517074845.0
264 0 _c20161213
008 201612s 0 0 eng d
022 _a1879-016X
024 7 _a10.1016/j.pharmthera.2016.01.007
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMichel, Martin C
245 0 0 _aβ3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project.
_h[electronic resource]
260 _bPharmacology & therapeutics
_cMar 2016
300 _a66-82 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAdrenergic beta-3 Receptor Agonists
_xpharmacology
650 0 4 _aAdrenergic beta-3 Receptor Antagonists
_xpharmacology
650 0 4 _aAnimals
650 0 4 _aAntibodies
_xpharmacology
650 0 4 _aDrug Repositioning
650 0 4 _aHumans
650 0 4 _aLigands
650 0 4 _aReceptors, Adrenergic, beta-3
_xgenetics
650 0 4 _aSyndrome
650 0 4 _aTranslational Research, Biomedical
650 0 4 _aUrinary Bladder
_xphysiology
650 0 4 _aUrinary Bladder, Overactive
_xdrug therapy
700 1 _aKorstanje, Cees
773 0 _tPharmacology & therapeutics
_gvol. 159
_gp. 66-82
856 4 0 _uhttps://doi.org/10.1016/j.pharmthera.2016.01.007
_zAvailable from publisher's website
999 _c25666833
_d25666833